Dimethyl Lithospermate B, an Extract of Danshen, Suppresses Arrhythmogenesis Associated With the Brugada Syndrome

Jeffrey M. Fish, DVM; Daniel R. Welchons; Young-Sup Kim, PhD; Suk-Ho Lee, MD, PhD; Won-Kyung Ho, MD, PhD; Charles Antzelevitch, PhD

Background—Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese herbal remedy, which slows inactivation of $I_{Na}$, leading to increased inward current during the early phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the setting of Brugada syndrome.

Methods and Results—The Brugada syndrome phenotype was created in canine arterially perfused right ventricular wedge preparations with the use of either terfenadine or verapamil to inhibit $I_{Na}$ and $I_{Ca}$, or pinacidil to activate $I_{K,ATP}$. AP recordings were simultaneously recorded from epicardial and endocardial sites together with an ECG. Terfenadine, verapamil, and pinacidil each induced all-or-none repolarization at some epicardial sites but not others, leading to ST-segment elevation as well as an increase in both epicardial and transmural dispersions of repolarization (EDR and TDR, respectively) from 12.9±9.6 to 107.0±54.8 ms and from 22.4±8.1 to 82.2±37.4 ms, respectively ($P<0.05$; $n=9$). Under these conditions, phase 2 reentry developed as the epicardial AP dome propagated from sites where it was maintained to sites at which it was lost, generating closely coupled extrasystoles and ventricular tachycardia and fibrillation. Addition of dmLSB (10 μmol/L) to the coronary perfusate restored the epicardial AP dome, reduced EDR and TDR to 12.4±18.1 and 24.4±26.7 ms, respectively ($P<0.05$; $n=9$), and abolished phase 2 reentry–induced extrasystoles and ventricular tachycardia and fibrillation in 9 of 9 preparations.

Conclusions—Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage. (Circulation. 2006;113:1393-1400.)

Key Words: action potentials ■ arrhythmia ■ antiarrhythmia agents ■ sudden death ■ reentry

The Brugada syndrome is a familial disease with an autosomal dominant mode of inheritance. It is characterized by ST-segment elevation in the right precordial leads and episodes of syncope and sudden cardiac death. To date, >100 mutations in SCN5A, the gene that encodes for the α-subunit of the cardiac sodium channel, have been linked to the Brugada syndrome (for review, see Antzelevitch et al.1 Priori et al.2 Antzelevitch,3 Balser,4 and Tan5). All known mutations result in a loss of sodium channel function.

Using the canine arterially perfused right ventricular wedge, our laboratory elucidated the mechanisms responsible for ST-segment elevation in the right precordial leads and the generation of lethal arrhythmias.6,7 The prominent transient outward current ($I_{to}$)–mediated notch in the action potential (AP) of the right ventricular epicardium plays a pivotal role in the arrhythmogenesis of the syndrome. A negative shift in the balance of currents active at the end of phase 1, namely, sodium current ($I_{Na}$), calcium current ($I_{Ca}$), and $I_{to}$, can result in all-or-none repolarization at the end of phase 1 (loss of the dome) in some areas of the epicardium but not the endocardium, leading to ST-segment elevation. As the dome propagates from regions where it is maintained to regions where it is lost, phase 2 reentry develops and gives rise to an extrasystole that precipitates polymorphic ventricular tachycardia and fibrillation (VT/VF). $I_{to}$ block, via its actions to restore the AP dome and suppress phase 2 reentry and VT/VF, has been suggested as a therapeutic strategy for the Brugada syndrome.6–10

In the present study we explore a novel therapeutic strategy for the Brugada syndrome by selectively enhancing sodium current with dimethyl lithospermate B (dmLSB), a minor component of the root extract from Salvia miltiorrhiza. Previous studies with dmLSB have demonstrated a slowing of inactivation of $I_{Na}$ without an increase in persistent late $I_{Na}$.11 We hypothesized that this action of dmLSB will prevent loss of the epicardial AP dome and be effective in preventing

Received November 14, 2005; revision received January 9, 2006; accepted January 13, 2006.

From the Masonic Medical Research Laboratory, Utica, NY (J.M.F., D.R.W., C.A.); Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea (S.L., W.H.); and National Research Laboratory for Cell Physiology and Department of Physiology, Seoul National University College of Medicine, Seoul, Republic of Korea (S.L., W.H.).

Correspondence to Dr Jeffrey M. Fish, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501-1787. E-mail fish@mmrl.edu

© 2006 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org

DOI: 10.1161/CIRCULATIONAHA.105.601690

1393
phase 2 reentry and VT/VF in the Brugada syndrome. To test this hypothesis, we examined the actions of dmLSB in 3 distinct pharmacological models of the Brugada syndrome.

**Methods**

The detailed methods used for isolation, perfusion, and recording of transmembrane activity from the arterially perfused canine right ventricular wedge preparation, as well as the viability and electric stability of the preparation, have been previously reported.

**Isolation of dmLSB From the Root Extract of *S. miltiorrhiza***

Dried roots of *S. miltiorrhiza* (6 kg) were soaked in MeOH for 7 days at room temperature. After filtration, the extract was concentrated under the reduced pressure to give 470 g of a dark syrupy MeOH extract. This was suspended in H2O and sequentially partitioned with n-hexane, EtOAc, and BuOH. This process yielded 69 g in the n-hexane fraction, 52 g in the EtOAc fraction, 69 g in the BuOH fraction, and a water-soluble residue. Half of the EtOAc fraction (26 g) was subjected to octadecyl silica gel column (2.4 g), fraction 2 was the most potent and was further purified by Sephadex LH-20 column chromatography with the use of 20% EtOAc in CH2Cl2, which finally delivered 110 mg of dmLSB in fraction 4. Moreover, LSB was easily converted to dmLSB by simple methylation of LSB in MeOH with the use of p-toluenesulfonic acid as catalyst. The chemical structure of dmLSB was elucidated with the use of 1H-NMR and 13C-NMR data. A stock solution of 20 mmol/L dmLSB was prepared in 100% dimethyl sulfoxide. The wedge preparations were exposed to dmLSB for a period of 30 minutes.

**Statistical Analysis**

Statistical analysis was performed with the use of 1-way ANOVA or Kruskal-Wallis ANOVA on ranks in combination with a Tukey test, as appropriate. Incidence data were analyzed with a Fisher exact test. All data are reported as mean ± SD.

The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
An inward shift in the balance of current active during the early phases of the right ventricular AP underlies the ECG and arrhythmic manifestations of the Brugada syndrome. In the right ventricular wedge preparation, such a shift can be achieved with the use of either agents that inhibit inward depolarizing current or agents that activate outward repolarizing current. We created the Brugada phenotype using both approaches. Verapamil was used to block inward calcium channel current ($I_{Ca}$), pinacidil to activate adenosine triphosph-

### Table 1. Epicardial AP Notch Parameters at Steady State (BCL=2000 ms)

<table>
<thead>
<tr>
<th>Brugada Syndrome Model</th>
<th>Epi 1 Notch Magnitude (as % of Phase 2 Amplitude)</th>
<th>Epi 1 Notch Index (Duration / Magnitude)</th>
<th>Epi 2 Notch Magnitude (as % of Phase 2 Amplitude)</th>
<th>Epi 2 Notch Index (Duration / Magnitude)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Terenadine (n=3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>29.5±4.1</td>
<td>39.0±9.0</td>
<td>1170.4±384.5</td>
<td>28.1±0.9</td>
</tr>
<tr>
<td>Terenadine (5 μmol/L)</td>
<td>45.1±6.6*</td>
<td>45.2±2.5</td>
<td>2046.9±361.1*</td>
<td>51.3±10.9*</td>
</tr>
<tr>
<td>+ dmLSB (10 μmol/L)</td>
<td>18.6±3.4§</td>
<td>24.1±7.7§</td>
<td>464.3±237.4</td>
<td>23.8±8.8§</td>
</tr>
<tr>
<td><strong>Verapamil (n=3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>32.4±0.9</td>
<td>44.9±3.6</td>
<td>1790.0±163.1</td>
<td>25.8±4.1</td>
</tr>
<tr>
<td>Verapamil (1–5 μmol/L)</td>
<td>59.5±10.2</td>
<td>49.0±3.3</td>
<td>3034.4±559.6*</td>
<td>50.6±11.4*</td>
</tr>
<tr>
<td>+ dmLSB (10 μmol/L)</td>
<td>18.4±0.3§</td>
<td>8.5±4.6§</td>
<td>1687.1±68.0</td>
<td>21.1±3.2§</td>
</tr>
<tr>
<td><strong>Pinacidil (n=3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>26.7±7.8</td>
<td>35.1±10.6</td>
<td>1681.5±197.6</td>
<td>26.8±8.4</td>
</tr>
<tr>
<td>Pinacidil (2–6 μmol/L)</td>
<td>49.6±7.8</td>
<td>43.3±10.3</td>
<td>2824.3±787.7</td>
<td>51.3±8.8*</td>
</tr>
<tr>
<td>+ dmLSB (10 μmol/L)</td>
<td>16.0±15.5§</td>
<td>16.8±18.1</td>
<td>1144.0±1027.8</td>
<td>5.6±9.8§</td>
</tr>
<tr>
<td><strong>All (n=9)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>29.6±5.1</td>
<td>39.6±8.4</td>
<td>1204.9±136.8</td>
<td>26.9±4.8</td>
</tr>
<tr>
<td>Brugada model</td>
<td>51.4±9.6‡</td>
<td>45.9±6.1</td>
<td>2366.7±602.9†</td>
<td>26.9±4.8‡</td>
</tr>
<tr>
<td>+ dmLSB (10 μmol/L)</td>
<td>17.7±8.1‡</td>
<td>16.4±12.1‡</td>
<td>358.2±353.4‡</td>
<td>16.8±10.9‡</td>
</tr>
</tbody>
</table>

* $P<0.05$ vs control.
† $P<0.01$ vs control.
‡ $P<0.001$ vs control.
§ $P<0.05$ vs terfenadine, verapamil, pinacidil, or Brugada model.
¶ $P<0.01$ vs terfenadine, verapamil, pinacidil, or Brugada model.
¶¶ $P<0.001$ vs terfenadine, verapamil, pinacidil, or Brugada model.
not late phases of the AP, dmLSB tended to abbreviate APD90, secondary to diminution of the AP notch.

Heterogeneous loss of the epicardial AP dome occurred in the presence of terfenadine, verapamil, or pinacidil, generating both local epicardial dispersion of repolarization (EDR) and transmural dispersion of repolarization (TDR) between the briefest epicardial response and that of endocardium. EDR and TDR values for each of the 3 Brugada syndrome models are summarized in Figure 4 and Table 3. With each treatment as well as with the combined data, EDR and TDR increased compared with control, although the increase in TDR did not reach statistical significance in the case of pinacidil. The addition of dmLSB (10 μmol/L) resulted in a significant decrease in EDR and TDR toward control values.

Figures 5 and 6 illustrate heterogeneous loss of the epicardial AP dome and phase 2 reentry in each of the 3 Brugada syndrome models. Phase 2 reentry occurred as the dome

**TABLE 2. APD90 at Steady State (BCL=2000 ms)**

<table>
<thead>
<tr>
<th>Brugada Syndrome Model</th>
<th>Epi 1 APD90 ms</th>
<th>Epi 2 APD90 ms</th>
<th>Endocardial APD90 ms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terfenadine (n=3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>215.7±9.7</td>
<td>213.2±8.6</td>
<td>242.7±11.6</td>
</tr>
<tr>
<td>Terfenadine (5 μmol/L)</td>
<td>239.0±14.4</td>
<td>231.1±12.4</td>
<td>251.8±6.4</td>
</tr>
<tr>
<td>+dmLSB (10 μmol/L)</td>
<td>212.8±13.2</td>
<td>202.3±6.9*</td>
<td>230.5±9.9</td>
</tr>
<tr>
<td>Verapamil (n=3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>240.2±19.4</td>
<td>223.0±18.4</td>
<td>249.0±12.1</td>
</tr>
<tr>
<td>Verapamil (1–5 μmol/L)</td>
<td>250.4±18.2</td>
<td>241.1±5.4</td>
<td>265.4±4.2</td>
</tr>
<tr>
<td>+dmLSB (10 μmol/L)</td>
<td>221.7±18.4</td>
<td>221.6±19.8</td>
<td>270.4±10.7</td>
</tr>
<tr>
<td>Pinacidil (n=3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>240.3±30.8</td>
<td>230.4±22.5</td>
<td>279.0±20.4</td>
</tr>
<tr>
<td>Pinacidil (2–6 μmol/L)</td>
<td>187.0±17.5</td>
<td>172.9±17.6*</td>
<td>195.4±38.3*</td>
</tr>
<tr>
<td>+dmLSB (10 μmol/L)</td>
<td>170.6±12.2*</td>
<td>163.0±14.1*</td>
<td>218.0±15.4</td>
</tr>
</tbody>
</table>

*P<0.05 vs control.
propagated from regions of the epicardium where it was maintained to regions at which it was lost. This mechanism generated closely coupled extrasystoles in all 9 preparations as well as polymorphic VT in 6 of 9 wedge preparations. Addition of dmLSB (10 \mu mol/L) abolished phase 2 reentry and all arrhythmic activity in 9 of 9 preparations (P<0.05 versus terfenadine, verapamil, or pinacidil; Table 3).

The effects of dmLSB (0.5 to 20 \mu mol/L) alone in the canine arterially perfused right ventricular wedge are illustrated in Figure 7. There was a concentration-dependent reduction in the size of the epicardial AP notch, although this did not reach statistical significance. APD and transmural dispersion were largely unaffected by dmLSB.

### Discussion

Our study demonstrates for the first time that delaying the inactivation of \( I_{Na} \) by as little as 20 ms can prevent the ECG and arrhythmic manifestations of the Brugada syndrome in our experimental models irrespective of the mechanism responsible for precipitating the disease. dmLSB is shown to prevent the development of all-or-none repolarization, phase 2 reentry, and the resultant closely coupled extrasystoles and polymorphic tachycardia in 3 different experimental models that mimic the Brugada syndrome. These data suggest that dmLSB may be a viable pharmacological alternative for the treatment of patients with the Brugada syndrome, as an adjunct to the use of implanted cardioverter/defibrillators (ICDs), or as an alternative in cases in which ICDs are not feasible or affordable.

dmLSB has previously been reported to slow the inactivation kinetics of \( I_{Na} \) by increasing the proportion of the slowly inactivating component, raising the possibility that it would prolong APD and QT interval, like ATX-II. Previous studies in rat ventricular myocytes demonstrate that inactivation of \( I_{Na} \) was complete within 50 ms after 10 \mu mol/L dmLSB, resulting in no increase in late \( I_{Na} \). In the present study, dmLSB alone had no significant effect on APD or TDR up to a dose of 20 \mu mol/L, suggesting no proarrhythmic effects of the drug (Figure 7).

A delicate balance of inward and outward currents determines the voltage at the end of epicardial AP phase 1. The 3 principal currents active at this point are \( I_{Na}, I_{Ca_L} \), and \( I_{Ca_T} \). Any manipulation resulting in a negative shift in the balance of these 3 currents at the end of epicardial AP phase 1 can result in an accentuated J wave as the epicardial AP notch becomes accentuated or ST-segment elevation as all-or-none repolarization at the end of epicardial phase 1 occurs. Terfenadine blocks late \( I_{Na} \) and \( I_{Ca_L} \) with an IC\(_{50}\) in canine ventricular myocytes of 1.3 and 1.1 \mu mol/L, respectively (A.C. Zygmunt, PhD, and C. Antzelevitch, PhD, unpublished data, 2001). Terfenadine also produces both tonic and use-dependent block of \( I_{Na} \) as was demonstrated in canine atrial myocytes. These effects of terfenadine make the epicardial AP notch become accentuated or ST-segment elevation as all-or-none repolarization at the end of epicardial phase 1 occurs. Terfenadine blocks late \( I_{Na} \) and \( I_{Ca_L} \) with an IC\(_{50}\) in canine ventricular myocytes of 1.3 and 1.1 \mu mol/L, respectively (A.C. Zygmunt, PhD, and C. Antzelevitch, PhD, unpublished data, 2001). Terfenadine also produces both tonic and use-dependent block of \( I_{Na} \) as was demonstrated in canine atrial myocytes. These effects of terfenadine make the epicardial AP notch more prominent by shifting the end of epicardial phase 1 to more negative voltages and delaying the onset of phase 2 (Figure 1A). This model of the Brugada syndrome was described and characterized in 2004. Similarly, verapamil inhibits \( I_{Ca_L} \) and late \( I_{Na} \) with an IC\(_{50}\) in canine ventricular myocytes of 0.31 and 0.21 \mu mol/L, respectively (A.C. Zygmunt, PhD, and C. Antzelevitch, PhD, unpublished data, 2001), resulting in a more prominent AP notch in the epicardium (Figure 1B). Verapamil has been shown in one

### Table 3. Maximal EDR and TDR and Incidence of Arrhythmias

<table>
<thead>
<tr>
<th>Brugada Syndrome Model</th>
<th>EDR</th>
<th>TDR</th>
<th>Phase 2 Polymorphic VT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tertfenadine (n=3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>5.9±3.2</td>
<td>15.2±10.8</td>
<td>0/3</td>
</tr>
<tr>
<td>Tertfenadine (5 \mu mol/L)</td>
<td>101.2±35.8</td>
<td>95.0±32.7</td>
<td>3/3</td>
</tr>
<tr>
<td>+dmLSB (10 \mu mol/L)</td>
<td>3.8±0.1</td>
<td>6.1±2.3</td>
<td>0/3</td>
</tr>
<tr>
<td>Verapamil (n=3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>18.3±7.6</td>
<td>17.9±4.5</td>
<td>0/3</td>
</tr>
<tr>
<td>Verapamil (1–5 \mu mol/L)</td>
<td>154.0±66.1*</td>
<td>104.8±40.5†</td>
<td>3/3</td>
</tr>
<tr>
<td>+dmLSB (10 \mu mol/L)</td>
<td>24.4±30.3§</td>
<td>39.6±41.3</td>
<td>0/3</td>
</tr>
<tr>
<td>Pinacidil (n=3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>14.6±13.6</td>
<td>29.8±8.3</td>
<td>0/3</td>
</tr>
<tr>
<td>Pinacidil (2–6 \mu mol/L)</td>
<td>66.4±22.7*</td>
<td>46.8±1.0</td>
<td>3/3</td>
</tr>
<tr>
<td>+dmLSB (10 \mu mol/L)</td>
<td>9.1±6.6§</td>
<td>30.9±16.8</td>
<td>0/3</td>
</tr>
<tr>
<td>All (n=9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>12.9±9.6</td>
<td>22.4±8.1</td>
<td>0/9</td>
</tr>
<tr>
<td>Brugada model</td>
<td>107.2±54.8*</td>
<td>82.2±37.4‡</td>
<td>9/9</td>
</tr>
<tr>
<td>+dmLSB (10 \mu mol/L)</td>
<td>12.4±18.1§</td>
<td>24.4±26.7¶</td>
<td>0/9§</td>
</tr>
</tbody>
</table>

*P<0.05 vs control. †P<0.01 vs control. §§P<0.001 vs control. ¶P<0.05 vs terfenadine, verapamil, pinacidil, or Brugada model. ‡P<0.01 vs terfenadine, verapamil, pinacidil, or Brugada model. §P<0.05 vs terfenadine, verapamil, pinacidil, or Brugada model. †P<0.01 vs terfenadine, verapamil, pinacidil, or Brugada model.
clinical case to create a Brugada-like phenotype. This model of the Brugada syndrome has also been previously described. Pinacidil activates the normally quiescent ATP-sensitive potassium current ($I_{\text{K-ATP}}$), resulting in a more pronounced epicardial AP notch (Figure 1C). The pinacidil model of the Brugada syndrome was first described in 1999. In all 3 models, the AP notch was significantly diminished after addition of dmLSB ($10 \mu\text{mol/L}$) because of the drug’s ability to slow the inactivation kinetics of $I_{\text{Na}}$, resulting in a positive shift in the balance of currents active at the end of epicardial AP phase 1. This was quantified by taking the amplitude difference between phases 1 and 2 (notch magnitude) as well as the interval between phase 0 and phase 2. The notch magnitude was normalized to the amplitude of phase 2 to account for the variable amplitude of the floating microelectrode impalement recordings.

The terfenadine-, verapamil-, or pinacidil-induced outward shift of current active during phase 1 of the AP leads to all-or-none repolarization at the end of phase 1 (loss of the dome) at some epicardial sites but not others, generating a local EDR as well as a TDR (Figure 4). These dispersions of repolarization and refractoriness create a vulnerable window for the generation of reentrant arrhythmias. Propagation of the epicardial AP dome from regions in which it is maintained to regions in which it is lost generates a closely coupled phase 2 reentrant extrasystole that captures the vulnerable window leading to the development of closely coupled extrasystoles and polymorphic VT (Figures 5 and 6). dmLSB ($10 \mu\text{mol/L}$) significantly reduces both TDR and EDR in our models of the Brugada syndrome by preventing heterogeneous loss of the epicardial AP dome and resulting AP abbreviation, secondary to an outward shift in the balance of currents active during phase 1 of the AP. This action of the drug effectively eliminated both the trigger and the substrate for reentry in 9 of 9 preparations tested.

Although all mutations thus far associated with the Brugada syndrome have been linked to SCN5A, mutations in this gene account for approximately 20% of Brugada syndrome cases, suggesting the likelihood that genetic defects linked to other ion channel currents active during the early phases of the AP may be involved, including $I_{\text{Na}}$, $I_{\text{K-ATP}}$, $I_{\text{Kr}}$, $I_{\text{Ks}}$, or $I_{\text{Ca}}$. The effectiveness of dmLSB in preventing Brugada syndrome induced in these 3 diverse pharmacological models suggests that this strategy may be effective in patients with Brugada syndrome induced by various etiologies.

Previous studies from our laboratory suggest block of $I_{\text{Na}}$ as a therapeutic strategy for the Brugada syndrome (for review, see Antzelevitch and Fish). Both $I_{\text{Na}}$ block and delay in the inactivation of $I_{\text{Na}}$ with dmLSB result in a positive shift in the
balance of currents active at the end of epicardial AP phase 1, making loss of the epicardial AP dome and phase 2 reentry unlikely.

ICD implantation is the mainstay of therapy for the Brugada syndrome. Although feasible, implantation is challenging in infants and is not an adequate solution for patients residing in regions of the world where an ICD is unaffordable. A pharmacological solution is desirable as an alternative to device therapy in these cases as well as in minimizing the firing of the ICD in patients with frequent events.1,10,16 Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to ICD usage.

Study Limitations
As with all in vitro experimental pharmacological models of human disease, caution must be exercised in extrapolating the results to the clinic. Although our models closely resemble the clinical syndrome with respect to ECG and arrhythmic manifestations, the full extent to which the models predict the behavior of the various congenital forms of the Brugada syndrome remains to be established.

Figure 7. Effect of dmLSB in the canine right ventricular wedge preparation. A, Transmural ECG and APs recorded from 2 epicardial sites and 1 endocardial site (Endo) in a canine arterially perfused wedge under control conditions and in the presence of dmLSB (0.5 to 20 μmol/L). BCL = 2000 ms. B, Effect of dmLSB (0.5 to 20 μmol/L) on the epicardial AP notch index (notch magnitude × notch duration; see Figure 2 for complete definition). BCL = 2000 ms; n = 3. C, Effect of dmLSB (0.5 to 20 μmol/L) on TDR and APD₉₀ in 2 epicardial and 1 endocardial AP. BCL = 2000 ms; n = 3.

Acknowledgments
This study was supported by grant HL47678 from the National Heart, Lung, and Blood Institute (C. Antzelevitch) and grants from the American Heart Association, Northeast Affiliate (J.M. Fish, D.R. Welchons, C. Antzelevitch), and NYS and Florida Grand Lodges F & AM. We gratefully acknowledge the technical assistance of Judy Hefferon and Robert Goodrow.

Disclosures
None.

References


Dimethyl Lithospermate B, an Extract of Danshen, Suppresses Arrhythmogenesis Associated With the Brugada Syndrome
Jeffrey M. Fish, Daniel R. Welchons, Young-Sup Kim, Suk-Ho Lee, Won-Kyung Ho and Charles Antzelevitch

Circulation. 2006;113:1393-1400; originally published online March 13, 2006; doi: 10.1161/CIRCULATIONAHA.105.601690

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/113/11/1393